Cogentix Medical Inc /de/ (CGNT): Lewis C Pell , director of Cogentix Medical Inc /de/ purchased 13,291 shares on Jun 10, 2016. The Insider buying transaction was reported by the company on Jun 14, 2016 to the Securities and Exchange Commission. The shares were purchased at $0.95 per share for a total value of $12,626.45 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 3, 2016, Lewis C Pell (director) purchased 894 shares at $0.75 per share price.On May 22, 2015, Kevin H Roche (director) purchased 10,000 shares at $1.65 per share price.
Cogentix Medical Inc (CGNT) witnessed a volatile trading activity on Friday Jun 10, 2016 and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $0.998 and reached the intraday high at $1. The bulls started the profit booking and pushed the shares to intraday low of $0.95. The trading session was marked by a volume range of 19,982 shares exchanging hands. The 52-week high of the shares is $1.72 and the 52-week low is $0.7121. The market cap of the company stands at $26 M and there are 2,59,52,785 shares in public circulation.
Cogentix Medical Inc. formerly Vision-Sciences Inc. is a medical device company. The Company designs develops manufactures and markets products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier EndoSheath technology. The Company produces and markets Endoscopes such as cystoscopes ureteroscopes laryngoscopes otoscopes sinuscopes trans-nasal esophagoscopy (TNE) and bronchoscopes for medical use and borescopes for industrial use and digital processing units (DPU). The Company offers Urgent PC Neuromodulation System a nerve stimulation device that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). It also offers Macroplastique an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence. It markets additional bulking agents: PTQ for the treatment of fecal incontinence and the VOX for vocal cord augmentation.